A new medicine for attention-deficit hyperactivity disorder (ADHD) has just entered the treatment toolbox: centanafadine, a once-a-day tablet sold under the brand name Simtriyo.
It has been approved in the United States for adults and children aged six years and older but isn’t yet available in Australia.